Symptoms and General Pathology

All Conditions

Infections

Immune System Diseases

Neoplasms

Blood and Lymph Conditions

Rare Diseases

Syndrome

Mycoses

Invasive Fungal Infections

Graft vs Host Disease

Preleukemia

Myelodysplastic Syndromes

Communicable Diseases

Bacterial Infections

Bacterial Infections and Mycoses

Bone Marrow Diseases

Hematologic Diseases

Precancerous Conditions

Homologous Wasting Disease

Acute Graft Versus Host Disease

Anti-Infective Agents

All Drugs and Chemicals

Micafungin

Clotrimazole

Miconazole

Antifungal Agents

treatment for 8 days with intravenous micafungin twice weekly

alternate dosing

daily dosing

micafungin

Roger Brüggemann

The primary objective of this trial is as follows:

To determine the pharmacokinetics of micafungin given twice weekly in patients at risk for developing an invasive fungal disease (patients who are being treated for acute or chronic graft versus host disease; patients receiving reduced intensity conditioning for Stem Cell Transplant (SCT); receiving first remission induction chemotherapy for Acute Myeloid Leucaemia (AML)/MyeloDysplasticSyndrome (MDS)) compared to the pharmacokinetics of micafungin given daily.

The secondary objective of this trial is as follows:

To determine whether adequate exposure of micafungin is attained. To determine the safety of micafungin in this patient population

Micafungin has been shown to be a reasonable option for treating invasive aspergillosis in hematopoietic stem cell transplantation (HSCT) recipients and has proven as effective as fluconazole for prophylaxis. Whilst micafungin has much to offer, little is known about its pharmacokinetic profile in specific patient populations, specifically concerning alternate dosing strategies with increased dosages over a prolonged dosing interval. Sufficient data are lacking up to now for twice weekly administration of micafungin as antifungal prophylaxis. Decreasing the dosing frequency to twice weekly seems a reasonable approach considering the long terminal elimination life (i.e. 10-17 h) and considering the data available from murine models that support the use of less frequent dosing with higher dosages.

It will enable us to characterize both the pharmacokinetics of micafungin in the hematology cohort and directly compare the exposure to the alternate dosing strategy.

Pharmacokinetics of Micafungin Given Twice Weekly Intravenously Compared to Micafungin Given Daily to Patients at Risk for Developing an Invasive Fungal Disease

Pharmacokinetics of Micafungin (Mycamin ®) as Antifungal Prophylaxis Given Twice Weekly Intravenously Compared to Micafungin Given Daily to Patients at Risk for Developing an Invasive Fungal Disease.

Full pharmacokinetic curves will be taken op Day 4 or 5 and Day 8 (micafungin). AUC of two dosing regimens will be compared.

to perform Monte Carlo simulations to provide the scientific background for alternate dosing strategies in the prophylactic setting

number and severity of adverse events will be recorded during the study and both treatment regimens will be compared

Radboud University Medical Center

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Pharmacokinetics of Micafungin Given Twice Weekly Intravenously Compared to Micafungin Given Daily to Patients at Risk for Developing an Invasive Fungal Disease	NCT02172768	Acute Graft Ver... Allogeneic Stem... Acute Myeloid L... Myelo Dysplasti...	alternate dosin... daily dosing micafungin	18 Years -	Radboud University Medical Center
Pharmacokinetics of Micafungin Given Twice Weekly Intravenously Compared to Micafungin Given Daily to Patients at Risk for Developing an Invasive Fungal Disease	NCT02172768	Acute Graft Ver... Allogeneic Stem... Acute Myeloid L... Myelo Dysplasti...	alternate dosin... daily dosing micafungin	18 Years -	Radboud University Medical Center

Spots Global Cancer Trial Database for alternate dosing